Grant R. Goodman - Concepedia

Author

Grant R. Goodman

Einstein Medical Center Philadelphia

Also Known As

G Goodman, G. R. Goodman, G.R Goodman, G.R. Goodman, Grant Goodman, Grant R Goodman, Grant R. Goodman

Publications

1.1K

Citations

H-Index

Concepts

All Affiliations

Einstein Medical Center Philadelphia Ospedale Papa Giovanni XXIII University of Utah German Cancer Research Center University of Colorado Denver

About

Grant R. Goodman is an author at Einstein Medical Center Philadelphia specializing in health sciences, medicine, and bone metabolism.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Health Sciences	4	4	312
2	Medicine	4	4	329
3	Immunology	3	3	276
4	Endocrinology	1	1	53
5	Metabolism	1	1	53

Grant R. Goodman

Publications

899

Citations

H-Index

Page 1

	Year	Citations
Extended Follow-Up of Patients With Hairy Cell Leukemia After Treatment With Cladribine Grant R. Goodman, Carol Burian, James A. Koziol, Journal of Clinical Oncology	2003	266
Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial Michele Maio, Karl D. Lewis, Lev Demidov, The Lancet Oncology MedicineMelanomaImmunologyClinical TrialsAdjuvant Vemurafenib	2018	210
MYCOPHENOLATE MOFETIL: A PROMISING NEW IMMUNOSUPPRESSANT THAT DOES NOT CAUSE BONE LOSS IN THE RAT1,2 Imara Dissanayake, Grant R. Goodman, Andrew R. Bowman, Transplantation	1998	83
Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAFv600 mutation–positive melanoma receiving adjuvant vemurafenib Paolo A. Ascierto, Karl D. Lewis, Anna Maria Di Giacomo, Annals of Oncology	2020	59
Immunosuppressant Use Without Bone Loss—Implications for Bone Loss After Transplantation Grant R. Goodman, Imara Dissanayake, Bali R. Sodam, Journal of Bone and Mineral Research	2001	56
Effect of the Interaction of Parathyroid Hormone and Cyclosporine A on Bone Mineral Metabolism in the Rat Sol Epstein, Imara Dissanayake, Grant R. Goodman, Calcified Tissue International Animal PhysiologyBone Mineral MetabolismMedicinePhysiologyParathyroid Hormone	2001	53
Pretreatment with Tocilizumab Prior to the CD3 Bispecific Cevostamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Showed a Marked Reduction in Cytokine Release Syndrome Incidence and Severity Suzanne Trudel, Nizar J. Bahlis, Andrew Spencer, Blood	2022	38
CAMMA 2: A phase I/II trial evaluating the efficacy and safety of cevostamab in patients with relapsed/refractory multiple myeloma (RRMM) who have triple-class refractory disease and have received a prior anti-B-cell maturation antigen (BCMA) agent. Shaji Kumar, Carlos Bachier, Michèle Cavo, Journal of Clinical Oncology Cancer ImmunosurveillanceOncologyMetronomic TherapyImmunologyTumor Immunity	2023	38
Interferon-α, unlike interferon-γ, does not cause bone loss in the rat Grant R. Goodman, Imara Dissanayake, E Gorodetsky, Bone InflammationBone DiseaseBone LossPhysiologyImmunology	1999	28
Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts David Carbone, Michael F. Sharpnack, Kai He, Journal of Translational Medicine	2018	28

Page 1